Response to Duovent of chronic reversible airways obstruction--a controlled trial in general practice
Abstract
A controlled trial was carried out in general practice comparing, in two successive 3 week periods, respiratory function in patients with chronic reversible airway obstruction treated, in the first period with their existing metered dose inhaler (MDI) and in the second period with Duovent , an MDI combining anticholinergic and beta2-stimulant agents respectively. One hundred and twenty-two patients were included. Peak expiratory flow rates were increased to a statistically significant degree during the Duovent period and, during this period, there was a significant reduction in day-time cough, night-time wheeze and night wakings . Global ratings by patients and physicians showed that 76% of patients improved with Duovent , and two-thirds of the patients preferred Duovent to their former MDI. Side effects with Duovent were mild, with dry mouth predominating.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)
- In silico and in vitro studies: investigating the chemical composition, DFT, molecular docking, and dynamic simulation of Satureja candidissima (Munby) Briq essential oil as a potential antibacterial agent
- Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus
- In silico study of the mechanism of action, pharmacokinetic and toxicological properties of some N-methylanthranilates and their analogs
- Anticonvulsant Effects of Citronellal, Daidzin, and Phytol, Possibly Through GABAA Receptor and Voltage-Gated Sodium Channel Interaction Pathways: In Vivo and In Silico Studies
- 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as D3R-Selective Ligands for 3D-QSAR, Docking and Molecular Dynamics Simulation Studies
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.